[Evaluation of the effect of splenectomy with autologous spleen tissue implantation in some monocyte functions in children with hepatosplenic schistosomiasis mansoni].
Adherence index, superoxide and TNF-alpha production in monocytes, with or without tuftsin treatment, were investigated in hepatosplenic schistosomiasis mansoni bearers with splenectomy with or without autologous implantation of spleen tissue. Three groups were evaluated: Healthy volunteers control group (CG) (n=12); Splenectomy with seft auto-transplant AG (n=18) and Splenectomy without auto-transplant WAG (n=9). Adherence index and TNF-alpha did not differ among the groups. Superoxide production was similar in CG and AG, in the 1st hour after cell stimulation. SP was larger in each hour time in CG and AG groups as compared WAS group. TT recovered normal pattern of SP in AG comparable with levels found in CG, with increase from the 1st to 2nd hour. However, TT did not alter SP in WAG, which remained reduced in all time points. Autologous implantation of spleen tissue seems to contribute for recovery and maintenance of the evaluated immunological reactions, which might be important in response to infections.
Brandt
Carlos T
CT
Departamento de Cirurgia, Universidade Federal de Pernambuco, Recife, PE.
Leite
Carlos Roberto C
CR
Manhaes-de-Castro
Raul
R
Brandt Filho
Carlos
C
Manhaes-de-Castro
Francisco M
FM
Barbosa-de-Castro
Celia Maria M
CM
D000293:Adolescent; D000328:Adult; D016022:Case-Control Studies; D002448:Cell Adhesion / Q000276:immunology; D005260:Female; D006801:Humans; D008109:Liver Diseases, Parasitic / Q000276:immunology / Q000469:parasitology / Q000601:surgery*; D008297:Male; D009000:Monocytes / Q000276:immunology / Q000502:physiology*; D012555:Schistosomiasis mansoni / Q000276:immunology / Q000601:surgery*; D013154:Spleen / Q000276:immunology / Q000637:transplantation*; D013156:Splenectomy; D013158:Splenic Diseases / Q000276:immunology / Q000469:parasitology / Q000601:surgery*; D013481:Superoxides / Q000276:immunology; D014182:Transplantation, Autologous / Q000379:methods; D016896:Treatment Outcome; D014405:Tuftsin / Q000008:administration & dosage; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D014409:Tumor Necrosis Factor-alpha; D013481:Superoxides; D014405:Tuftsin